𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations

✍ Scribed by Michael Schüpbach; Ebba Lohmann; Mathieu Anheim; Suzanne Lesage; Virginie Czernecki; Sadek Yaici; Yulia Worbe; Perrine Charles; Marie-Laure Welter; Pierre Pollak; Alexandra Dürr; Yves Agid; Alexis Brice

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
55 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Stimulation of the subthalamic nucleus (STN) improves motor signs in patients with levodopa-responsive Parkinson's disease (PD). Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause Parkinsonism. We assessed 69 patients under STN stimulation and found heterozygous LRRK2 mutations in 9 (G2019S in 8 and T2031S in 1). The age at onset of PD, the clinical characteristics before or after neurosurgery, and the clinical response to STN stimulation were similar in both groups. Two patients with the G2019S LRRK2 mutation still benefited from STN stimulation, 9 and 10 years after surgery. Patients with LRRK2 mutations are, therefore, good candidates for STN stimulation.

📜 SIMILAR VOLUMES

Contrast sensitivity in Parkinson's dise
Contrast sensitivity in Parkinson's disease patients with subthalamic nucleus deep brain stimulation
✍ Kelvin L. Chou; Melissa M. Amick; Margaret Gagner 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 457 KB 👁 1 views

## Abstract This study examined whether deep brain stimulation (DBS) would affect the contrast sensitivity (CS) curve in patients with PD. CS was tested in 12 nondemented PD patients treated with bilateral subthalamic nucleus DBS on and off stimulation and medications. Neither stimulation condition

Long-term efficacy and mortality in Park
Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation
✍ Mathias Toft; Bård Lilleeng; Jon Ramm-Pettersen; Inger Marie Skogseid; Vidar Gun 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 678 KB

## Background: The objective of this study was to examine the clinical outcome and mortality of long-term deep brain stimulation of the subthalamic nucleus in advanced parkinson's disease. ## Methods: We included all 144 patients (mean age, 60.3 years; mean disease duration, 11.0 years) treated i

Mortality in patients with Parkinson's d
Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus
✍ Michael W.M. Schüpbach; Marie Laure Welter; Anne Marie Bonnet; Alexis Elbaz; Bra 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients tr

LRRK2 mutations and risk variants in Jap
LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease
✍ Cyrus P. Zabetian; Mitsutoshi Yamamoto; Alexis N. Lopez; Hiroshi Ujike; Ignacio 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

## Abstract Mutations in the leucine‐rich repeat kinase 2 (__LRRK2__) gene are the most common genetic determinant of Parkinson's disease (PD) in European‐derived populations, but far less is known about __LRRK2__ mutations and susceptibility alleles in Asians. To address this issue, we sequenced t

Expectation and the placebo effect in Pa
Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation
✍ Rodrigo Mercado; Constantine Constantoyannis; Tomasz Mandat; Ajit Kumar; Michael 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

## Abstract To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus–deep brain stimulation (STN‐DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN‐DBS